Regeneris Medical

Focus: Regeneris Medical is a Massachusetts-based stem cell biotech focused on autologous cell therapies for orthopedics, aging, and sexual wellness applications. The company operates as a public entity with a narrow, regenerative medicine-focused pipeline.

Cell Therapy Musculoskeletal

Profile data last refreshed Yesterday · AI intelligence enriched 1w ago

Funding Stage

PUBLIC

Open Jobs

About Regeneris Medical

AI assessmentNot Hiring

No open roles listed right now. Follow Regeneris Medical to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

4 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Normal Saline

Osteoarthritis

N/A

tSVF by lipoaspiration

Alopecia Areata

N/A

Microcannula Harvest Adipose

Help build intelligence for Regeneris Medical

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Exposure to cutting-edge stem cell and regenerative medicine modalities with expanding clinical application areas including COVID-19, alopecia, dementia, and osteoarthritis
Early-stage company (founded 2011, public status) offers potential equity upside and cross-functional involvement compared to larger pharma structures
Autologous cell therapy is a high-growth segment with fewer competitors than traditional small molecule or mAb spaces

Watch Out For

Only 1 active clinical trial (Phase 1 for autologous adipose MSCs in COVID-19 pneumonia) signals minimal near-term pipeline momentum and limited clinical validation runway
Zero active job postings and no hiring department data indicate potential organizational contraction or talent freeze
Missing financial data (revenue, R&D spend, cash position) prevents assessment of long-term stability and funding runway

Generated by Claude from Regeneris Medical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Autologous Adipose MSC's

Covid-19 Pneumonia

Phase 1

Clinical Trials (1)

NCT04352803Adipose Mesenchymal Cells for Abatement of SARS-CoV-2 Respiratory Compromise in COVID-19 Disease

Phase 1

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2011

Portfolio: 1 clinical trial

Top TAs: Infectious Diseases

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Infectious Diseases

1 pipeline

Marketed

Pipeline